Sector ratings Savara Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
5.090 ^USD	-3.96%		-2.12%	-15.59%

05-18	Savara Inc Announces New Exercise Capacity Data From The IMPALA-2 Phase 3 Clinical Trial Of Molgramostim Inhalation Solution In Autoimmune Pulmonary Alveolar Proteinosis	CI
05-12	Savara Q1 Loss Widens	MT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation	Visibility
SAVARA INC.	1.29B	-	BB	-	-
ARGENX SE	55.01B		A
WUXI APPTEC CO., LTD.	43.37B		AAA
BIONTECH SE	22.27B	-	-	-	-
INSMED INCORPORATED	20.42B	-	A	-	-
WUXI BIOLOGICS (CAYMAN) INC.	17.27B		AAA
GENMAB A/S	15.02B		A
EXELIXIS, INC.	13.25B		BB
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	11.71B	-	AA	-	-
SUMMIT THERAPEUTICS INC.	11.46B	-	-	-	-
MADRIGAL PHARMACEUTICALS, INC.	11.23B	-	B	-	-
PHARMAESSENTIA CORPORATION	11.03B		AA
AKESO, INC.	11B		B
ARROWHEAD PHARMACEUTICALS, INC.	10.3B	-	BB	-	-
CYTOKINETICS, INCORPORATED	9.7B	-	AA	-	-
IMMUNITYBIO, INC.	7.25B	-	CCC	-	-
NUVALENT, INC.	7.18B	-	CCC	-	-
REMEGEN CO., LTD.	7.17B		-
SAMSUNG EPIS HOLDINGS CO., LTD.	7.1B		AA			-
BIOCON LIMITED	7B		B
Average	15B		A
Weighted average by Cap.			A